102 related articles for article (PubMed ID: 8144860)
1. Immunoscintigraphy with anti-chromogranin A antibodies in patients with endocrine/neuroendocrine tumors.
Colombo P; Paganelli G; Magnani P; Songini C; Fazio F; Faglia G
J Endocrinol Invest; 1993 Nov; 16(10):841-3. PubMed ID: 8144860
[No Abstract] [Full Text] [Related]
2. Imaging of bronchial carcinoid tumors associated to Cushing syndrome with 111In-Octreoscan scintigraphy and immunoscintigraphy with anti-chromogranin monoclonal antibodies. Report of two cases.
Carretta A; Chiesa G; Magnani P; Songini C; Melloni G; Zannini P; Grossi A
J Cardiovasc Surg (Torino); 1997 Apr; 38(2):191-4. PubMed ID: 9201136
[TBL] [Abstract][Full Text] [Related]
3. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
4. In vivo imaging of chromogranin A-positive endocrine tumours by three-step monoclonal antibody targeting.
Siccardi AG; Paganelli G; Pontiroli AE; Pelagi M; Magnani P; Viale G; Faglia G; Fazio F
Eur J Nucl Med; 1996 Nov; 23(11):1455-9. PubMed ID: 8854841
[TBL] [Abstract][Full Text] [Related]
5. Combined use of 111In-labeled pentetreotide and three-step immunoscintigraphy with antichromogranin A monoclonal antibody in the diagnosis of pituitary adenomas.
Magnani P; Paganelli G; Siccardi AG; Songini C; Colombo P; Faglia G; Fazio F
Cell Biophys; 1994; 24-25():307-13. PubMed ID: 7736536
[TBL] [Abstract][Full Text] [Related]
6. Pituitary and adrenal CT of Cushing syndrome.
Pojunas KW; Daniels DL; Williams AL; Thorsen MK; Haughton VM
AJR Am J Roentgenol; 1986 Jun; 146(6):1235-8. PubMed ID: 3010686
[TBL] [Abstract][Full Text] [Related]
7. Three-step immunoscintigraphy with anti-chromogranin A monoclonal antibody in tumours of the pituitary region.
Colombo P; Siccardi AG; Paganelli G; Magnani P; Songini C; Buffa R; Faglia G; Fazio F
Eur J Endocrinol; 1996 Aug; 135(2):216-21. PubMed ID: 8810736
[TBL] [Abstract][Full Text] [Related]
8. Secretion of chromogranin A by peptide-producing endocrine neoplasms.
O'Connor DT; Deftos LJ
N Engl J Med; 1986 May; 314(18):1145-51. PubMed ID: 3007986
[TBL] [Abstract][Full Text] [Related]
9. Is magnetic resonance imaging more sensitive than computed tomography in the location of corticotropin secreting pituitary adenomas?
Isaia GC; Limone P; Bodrato L; Avataneo T; Potenzoni F; Gremo L; Molinatti GM
Ann Ital Med Int; 1989; 4(2):122-4. PubMed ID: 2562003
[TBL] [Abstract][Full Text] [Related]
10. Chromogranin A in human neuroendocrine tumors: an immunohistochemical study with region-specific antibodies.
Portel-Gomes GM; Grimelius L; Johansson H; Wilander E; Stridsberg M
Am J Surg Pathol; 2001 Oct; 25(10):1261-7. PubMed ID: 11688460
[TBL] [Abstract][Full Text] [Related]
11. Case 18: adrenocorticotropic hormone-dependent Cushing syndrome.
Choyke PL; Doppman JL
Radiology; 2000 Jan; 214(1):195-8. PubMed ID: 10644123
[No Abstract] [Full Text] [Related]
12. Pituitary adenomas. An immunohistochemical study of hormone production and chromogranin localization.
DeStephano DB; Lloyd RV; Pike AM; Wilson BS
Am J Pathol; 1984 Sep; 116(3):464-72. PubMed ID: 6089568
[TBL] [Abstract][Full Text] [Related]
13. [Pathological study on thoracic carcinoids accompanied with Cushing's syndrome].
Liu HR; Liu TH; Lu ZL
Zhonghua Bing Li Xue Za Zhi; 1994 Dec; 23(6):351-4. PubMed ID: 7720114
[TBL] [Abstract][Full Text] [Related]
14. Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion.
Lamberts SW; de Lange SA; Stefanko SZ
J Clin Endocrinol Metab; 1982 Feb; 54(2):286-91. PubMed ID: 6274899
[No Abstract] [Full Text] [Related]
15. Cushing syndrome: pituitary CT scanning.
Saris SC; Patronas NJ; Doppman JL; Loriaux DL; Cutler GB; Nieman LK; Chrousos GP; Oldfield EH
Radiology; 1987 Mar; 162(3):775-7. PubMed ID: 3809493
[TBL] [Abstract][Full Text] [Related]
16. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
Korbonits M; Jacobs RA; Aylwin SJ; Burrin JM; Dahia PL; Monson JP; Honegger J; Fahlbush R; Trainer PJ; Chew SL; Besser GM; Grossman AB
J Clin Endocrinol Metab; 1998 Oct; 83(10):3624-30. PubMed ID: 9768675
[TBL] [Abstract][Full Text] [Related]
17. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas.
Nobels FR; Kwekkeboom DJ; Coopmans W; Hoekstra R; De Herder WW; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1993 Sep; 77(3):784-9. PubMed ID: 7690365
[TBL] [Abstract][Full Text] [Related]
18. [A case of an adenoma secreting ACTH].
Reverdin A; Favre L
Rev Med Suisse Romande; 1980 Apr; 100(4):355-7. PubMed ID: 6258209
[No Abstract] [Full Text] [Related]
19. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
Kimura N; Hoshi S; Takahashi M; Takeha S; Shizawa S; Nagura H
J Urol; 1997 Feb; 157(2):565-8. PubMed ID: 8996358
[TBL] [Abstract][Full Text] [Related]
20. Assessment of chromogranin A using two-site immunoassay. Selection of a monoclonal antibody pair unaffected by human chromogranin A processing.
Degorce F
Adv Exp Med Biol; 2000; 482():339-50. PubMed ID: 11192594
[No Abstract] [Full Text] [Related]
[Next] [New Search]
